→ Shares of Belgium’s argenx $ARGX edged up this morning as the company touted top-line data from its Phase II study of efgartigimod (ARGX-113) in adult primary immune thrombocytopenia patients. Researchers said that the drug spurred “clinically meaningful platelet count improvements across doses and ITP patient classifications, including newly diagnosed, persistent and chronic, and correlated with a consistent reduction in IgG levels.”
→ Boehringer Ingelheim underscored the growing importance of real-world data today with its results from the OTIVACTO study, an observational study involving 7,443 COPD patients treated with Spiolto Respimat (tiotropium/olodaterol). “Patients in the study reported both improved physical functioning and general condition and high satisfaction with their inhalation device and treatment overall. The improvements were observed in patients across disease severities,” the company noted.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,500+ biopharma pros who read Endpoints News by email every day.Free Subscription